Table 1.
The detailed information of AS patients
| Parameter | Baseline (Mean ± SD, N = 79) | Week 2 (Mean ± SD, N = 79) | Week 4(Mean ± SD, N = 79) | Week 8 (Mean ± SD, N = 79) | Week 12 (Mean ± SD. N = 79) |
|---|---|---|---|---|---|
| Male n (%) | 70 (89) | ||||
| age | 36.0 ± 11.5 | ||||
| HLA-B27 (%) | 98.7 | ||||
| disease duration (months) | 7.3 ± 8.0 | ||||
| NSAIDS (%) | 82.3 | ||||
| Psoriasis (%) | 0 | ||||
| Rheumatoid Arthritis (%) | 0 | ||||
| Inflammatory Bowel Disease | 0 | ||||
| BASDAI | 5.4 ± 1.0 | 3.4 ± 1.5 | 2.2 ± 1.1 | 1.7 ± 1.0 | 1.4 ± 0.8 |
| BASFI | 3.2 ± 2.2 | 2.1 ± 1.8 | 1.4 ± 1.5 | 1.1 ± 1.2 | 0.9 ± 1.1 |
| CRP | 20.8 ± 32.2 | 3.8 ± 9.9 | 3.7 ± 10.0 | 3.1 ± 4.9 | 3.1 ± 4.2 |
| ESR | 28.3 ± 31.1 | 11.4 ± 19.7 | 8.4 ± 13.1 | 6.3 ± 6.8 | 6.5 ± 7.1 |
| ASDAS | 3.4 ± 0.8 | 1.8 ± 0.7 | 1.5 ± 0.7 | 1.2 ± 0.6 | 1.1 ± 0.7 |
SD Standard deviation, BASDAI Bath Ankylosing Spondylitis Di, BASFI Bath Ankylosing Spondylitis Fu, ESR Erythrocyte sedimentation rate, CRP C reactive protein, ASDAS Ankylosing Spondylitis Disease NSADIS Non-steroidal anti-inflammator